MGH runs the clinical fusion assay for all lung cancer patients and the Snapshot NGS test on all patients with solid tumors. It is planning to expand the assays and is also developing a fusion panel for hematological malignancies.
While microarrays are quickly replacing traditional karyotyping in constitutional cytogenetic testing, the technology is also beginning to displace conventional methods for the clinical diagnosis of hematological cancers, according to a report by researchers from several European
The release of the new software comes at a time when BlueGnome has been adding sales personnel in Europe and North America to handle its cytogenetics customers. The firm also plans to establish an office in the US later this year.